134 related articles for article (PubMed ID: 10195630)
1. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Alves CR; Coutinho SG; Oliveira MP; Bertho AL; Toledo VP; Costa CA; Genaro O; Mendonça SC
Vaccine; 1999 Mar; 17(9-10):1179-85. PubMed ID: 10195630
[TBL] [Abstract][Full Text] [Related]
2. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis.
Mendonca SC; De Luca PM; Mayrink W; Restom TG; Conceicao-Silva F; Da-Cruz AM; Bertho AL; Da Costa CA; Genaro O; Toledo VP
Am J Trop Med Hyg; 1995 Aug; 53(2):195-201. PubMed ID: 7677224
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Pinto JA; Coutinho SG; Santiago MA; Toledo VP; Costa CA; Genaro O; Reis AB; Mendonça SC
Acta Trop; 2001 Dec; 80(3):251-60. PubMed ID: 11700183
[TBL] [Abstract][Full Text] [Related]
4. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
[TBL] [Abstract][Full Text] [Related]
5. Dichotomy of protective cellular immune responses to human visceral leishmaniasis.
Khalil EA; Ayed NB; Musa AM; Ibrahim ME; Mukhtar MM; Zijlstra EE; Elhassan IM; Smith PG; Kieny PM; Ghalib HW; Zicker F; Modabber F; Elhassan AM
Clin Exp Immunol; 2005 May; 140(2):349-53. PubMed ID: 15807861
[TBL] [Abstract][Full Text] [Related]
6. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
[TBL] [Abstract][Full Text] [Related]
7. In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.
Telino E; De Luca PM; Matos DC; Azeredo-Coutinho RB; Meirelles MN; Conceição-Silva F; Schubach A; Mendonça SC
Clin Exp Immunol; 2006 Feb; 143(2):338-44. PubMed ID: 16412059
[TBL] [Abstract][Full Text] [Related]
8. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production.
Castés M; Blackwell J; Trujillo D; Formica S; Cabrera M; Zorrilla G; Rodas A; Castellanos PL; Convit J
Vaccine; 1994 Aug; 12(11):1041-51. PubMed ID: 7975845
[TBL] [Abstract][Full Text] [Related]
9. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
Skeiky YA; Guderian JA; Benson DR; Bacelar O; Carvalho EM; Kubin M; Badaro R; Trinchieri G; Reed SG
J Exp Med; 1995 Apr; 181(4):1527-37. PubMed ID: 7699334
[TBL] [Abstract][Full Text] [Related]
10. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopina M; Hidalgo A; Cevallos W; Correa J
Vaccine; 2004 Mar; 22(9-10):1320-6. PubMed ID: 15003662
[TBL] [Abstract][Full Text] [Related]
12. Protection of C57BL/10 mice by vaccination with association of purified proteins from Leishmania (Leishmania) amazonensis.
Mora AM; Mayrink W; Costa RT; Costa CA; Genaro O; Nascimento E
Rev Inst Med Trop Sao Paulo; 1999; 41(4):243-8. PubMed ID: 10564919
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.
Satti IN; Osman HY; Daifalla NS; Younis SA; Khalil EA; Zijlstra EE; El Hassan AM; Ghalib HW
Vaccine; 2001 Feb; 19(15-16):2100-6. PubMed ID: 11228382
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
15. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease.
Amaral VF; Teva A; Oliveira-Neto MP; Silva AJ; Pereira MS; Cupolillo E; Porrozzi R; Coutinho SG; Pirmez C; Beverley SM; Grimaldi G
Mem Inst Oswaldo Cruz; 2002 Oct; 97(7):1041-8. PubMed ID: 12471434
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test.
De Luca PM; Mayrink W; Santiago MA; Nogueira R; Conceição-Silva F; Mélo G; Mendonça SC
Trans R Soc Trop Med Hyg; 2003; 97(6):709-12. PubMed ID: 16117969
[TBL] [Abstract][Full Text] [Related]
18. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
19. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.
Grenfell RF; Marques-da-Silva EA; Souza-Testasicca MC; Coelho EA; Fernandes AP; Afonso LC; Rezende SA
Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):818-22. PubMed ID: 20944999
[TBL] [Abstract][Full Text] [Related]
20. Short report: evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis.
Mayrink W; Pinto J; Da Costa C; Toledo V; Guimarães T; Genaro O; Vilela L
Am J Trop Med Hyg; 1999 Aug; 61(2):294-5. PubMed ID: 10463682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
